An adherence based cost–consequence model comparing bimatoprost 0.01% to bimatoprost 0.03%

By Wong William B.   Patel Vaishali D.   Kowalski Jonathan W.   Schwartz Gail  

Current Medical Research and Opinion, Vol. 29, Iss. 9, 2013-09 ,pp. : 1191-1200

Informa Healthcare

Access to resources Recommend Favorite

Comparison of adherence and persistence with bimatoprost 0.01% versus bimatoprost 0.03% topical ophthalmic solutions

By Campbell Joanna H.   Schwartz Gail   LaBounty Britni   Kowalski Jonathan   Patel Vaishali D.  

Current Medical Research and Opinion, Vol. 29, Iss. 9, 2013-09 ,pp. : 1201-1209

Informa Healthcare

Access to resources Recommend Favorite

A consensus approach to improving patient adherence and persistence with topical treatment for actinic keratosis

By  

INTERNATIONAL JOURNAL OF DERMATOLOGY, Vol. 54, Iss. 5, 2015-05 ,pp. : 509-515

John Wiley & Sons Inc

Access to resources Recommend Favorite

Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products

By Bullano Michael F.   Al-Zakwani Ibrahim S.   Fisher Maxine D.   Menditto Laura   Willey Vincent J.  

Current Medical Research and Opinion, Vol. 21, Iss. 2, 2005-02 ,pp. : 291-298

Informa Healthcare

Access to resources Recommend Favorite

A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension

By Palmer Andrew J.   Valentine William J.   Tucker Daniel M. D.   Ray Joshua A.   Roze Stéphane   Annemans Lieven   Lapuerta Pablo   Chen Roland   Gabriel Sylvie   Carita Paulo   Rodby Roger A.   de Zeeuw Dick   Parving Hans-Henrik   Laville Maurice  

Current Medical Research and Opinion, Vol. 22, Iss. 11, 2006-11 ,pp. : 2095-2100

Informa Healthcare

Access to resources Recommend Favorite